Celsion Announces Positive Interim Data from Phase 2 DIGNITY Trial in Breast Cancer

[PR Newswire] – LAWRENCEVILLE, N.J., Feb. 27, 2014 /PRNewswire/ — Celsion Corporation (CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC). The trial more

View todays social media effects on CLSN

View the latest stocks trending across Twitter. Click to view dashboard

See who Celsion is hiring next, click here to view